Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now later-stage tilt small index

Fluid Overload: later-stage trial registry

5 of 9 indexed Fluid Overload trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Fluid Overload: 9 US clinical trials tracked, 5 recruiting.

Fluid Overload is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Olive View-UCLA Education & Research Institute, running 1 of these trials.

Enrollment posture brief

Registry condition fluid-overload

OPEN 5 | RECR 56% | LATE 1 | EARLY 0 | RANK #1916 | SPON 1

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Fluid Overload (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Fluid Overload

Fluid Overload lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fluid Overload on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fluid Overload is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Fluid Overload trials is spread across many organizations.

    Olive View-UCLA Education & Research Institute accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Fluid Overload enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Fluid Overload research leans observational.

    3 interventional and 6 observational studies make up this index (33.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Open and recent trials

9 total, page 1 of 1

RECRUITING NA 400 participants

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

Lenox Hill Hospital

NCT06418022

RECRUITING NA 372 participants

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

Nuwellis

NCT05318105

RECRUITING 150 participants

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

University of Michigan

NCT05505500

RECRUITING 90 participants

Concordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS)

Indiana University

NCT07178470

RECRUITING 50 participants

The Effect of Fluids on Aortic VTI During C-section

Baylor College of Medicine

NCT04330742

ACTIVE NOT RECRUITING 36 participants

Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

Medtronic - MITG

NCT04608149

COMPLETED 125 participants

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04095143

COMPLETED 50 participants

Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients

Olive View-UCLA Education & Research Institute

NCT02679625

COMPLETED Phase 4 20 participants

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

Sarfez Pharmaceuticals

NCT06995144

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Fluid Overload records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Immedate Release Torsemide Tablets Drug
1 trials
Extended Release Torsemide Tablets Drug
1 trials
Ultrasound and NICOM Device
1 trials
Dimensions of the inferior vena cava Diagnostic test
1 trials
Pulmonary B-lines Diagnostic test
1 trials
Hepatic vein flow Diagnostic test
1 trials
Intra-renal flow Diagnostic test
1 trials
Portal vein flow Diagnostic test
1 trials

US sites by state

Facility locations filed on Fluid Overload trials. A trial with sites in several states counts in each.

Texas 3 trials
New York 3 trials
Ohio 2 trials
Michigan 2 trials
Kentucky 2 trials
Florida 2 trials
California 2 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fluid Overload page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fluid Overload condition card totals 9 registered trials; most-linked intervention Immedate Release Torsemide Tablets; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.